New data on burden of HAE treatment in children with HAE presented at scientific conferences

The significant unmet needs that exist for children living with HAE and their caregivers has been illustrated in new data from pharmaceutical company KalVista, presented at the recent ISPOR, and the Eastern Allergy Conference.

Reflecting on the data, Chief Medical Officer of KalVista, Paul Audhya, said: “We consistently see a substantial treatment burden for young children with HAE and their caregivers, often resulting in treatment avoidance or long delays in on-demand treatment. We also observe high rates of anxiety among children and caregivers related to injectable treatments. We believe these challenges drive higher-than-expected healthcare resource utilization, including emergency room visits and home healthcare support for treatment administration.”

Ben Palleiko, Chief Executive Officer of KalVista, said: “Across real-world treatment patterns, healthcare resource utilization, and caregiver experiences, these findings reinforce the need for new treatment options that are easy to use and support early, consistent treatment of attacks.

(Source: KalVista)